Arca
Skip to content
Tools
Tools

Label Changes: Hympavzi (marstacimab-hncq)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Hympavzi label DailyMed has published, from Pfizer Laboratories Div Pfizer Inc, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 8
  • Sections changed, version 7 to 8: 10, Including the boxed warning

What changed from version 7 to version 8

Jun 23, 2026 to Nov 16, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Boxed warningNew section · 52 words added
  2. Dosage and administrationChanged · 3 words added
  3. Warnings and precautionsChanged · 217 words added, 115 removed
  4. Use in specific populationsChanged · 1 removed
  5. Patient counseling informationChanged · 124 words added, 59 removed
  6. Patient informationChanged · 47 words added, 5 removed
  7. PRINCIPAL DISPLAY PANEL – 150 mg/mL Prefilled PenChanged · 1 word added, 1 removed
  8. PRINCIPAL DISPLAY PANEL – 150 mg/mL Prefilled Pen CartonChanged · 1 removed
  9. PRINCIPAL DISPLAY PANEL - 150 mg/mL Prefilled SyringeChanged · 1 word added, 1 removed
  10. PRINCIPAL DISPLAY PANEL - 150 mg/mL Prefilled Syringe CartonChanged · 1 removed

Boxed warning

New section52 words added
WARNING: THROMBOEMBOLIC EVENTS
• Venous and arterial thromboembolic events were reported in patients treated with HYMPAVZI with thrombotic risk factors [see Warnings and Precautions (5.1)].
• Monitor patients for signs or symptoms of thromboembolism and interrupt use of HYMPAVZI if these occur and manage as clinically indicated [see Warnings and Precautions (5.1)].

Dosage and administration

Changed3 words added
36 unchanged lines
For major surgery, pause HYMPAVZI at least 7 days prior and initiate management per local standard of care with clotting factor concentrate or bypassing agent and measures to manage the risk of venous thrombosis which can be elevated in the perioperative period. Consult the product information for the clotting factor concentrate or bypassing agent for dosage guidelines in patients with hemophilia undergoing major surgery. Resumption of HYMPAVZI therapy should consider the overall clinical status of the patient, including the presence of post-surgical thromboembolic risk factors, use of other hemostatic products and other concomitant medications [see Dosage and Administration (2.1)].
Management in Patients with Acute Severe Illness There is limited experience with the use of HYMPAVZI in patients with acute severe illness. Reasons to consider temporary dose interruption of HYMPAVZI include occurrence of acute severe illness (e.g., serious infection, sepsis, trauma, crush injuries, cancer) in which there may be increased activation of coagulation and which the healthcare provider considers could increase the risks associated with HYMPAVZI administration. Treatment of acute severe illness should be managed per local standard of care, and continued treatment with HYMPAVZI in this situation should be weighed against the potential risks involved. Resume HYMPAVZI therapy once patient has clinically recovered [see Dosage and Administration (2.1)].
2.7 Pregnancy Testing
3 unchanged lines

Warnings and precautions

Changed217 words added, 115 removed
1 unchanged line
5.1 Thromboembolic Events
HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist, and may increase the risk of thromboembolic complications. Venous and arterial thromboembolic events were reported in 0.8% of patients (2/259) treated with HYMPAVZI in the open-label extension study [see Adverse Reactions (6.1)].
HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist, and may increase the risk of thromboembolic complications. Venous and arterial thromboembolic events were reported in 0.8% of patients (2/259) treated with HYMPAVZI in the open-label extension study [see Adverse Reactions (6.1)] , including one patient with inhibitors who died due to complications resulting from an event of cerebral infarction post-surgery. These cases occurred in patients with multiple risk factors for thromboembolic events. Thromboembolic events were also reported in the postmarketing setting.
Patients with independent risk factors for thromboembolic events may be at increased risk of thromboembolic events with use of HYMPAVZI.
Risk factors for thromboembolism may include the use of high and/or frequent doses of breakthrough bleed treatments (factor products or bypassing agents) or conditions in which tissue factor is overexpressed (e.g., atherosclerotic disease, crush injury, cancer, disseminated intravascular coagulation, thrombotic microangiopathy, or septicemia).
Monitor patients for signs or symptoms of thromboembolism and interrupt use of HYMPAVZI if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated.
HYMPAVZI has not been studied in patients with a history of previous thromboembolic events [see Clinical Studies (14.1)]. Consider the benefit and risk of using HYMPAVZI in patients with known risk factors for thromboembolism.
Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated.
If factor VIII or factor IX products or bypassing agents are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose according to the product label is recommended [see Dosage and Administration (2.5) ].
If factor VIII or factor IX products or bypassing agents are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose according to the product label is recommended [see Dosage and Administration (2.5) ]. Inform patients of signs and symptoms of thromboembolic events. Monitor patients for thromboembolic events. If a thromboembolic event is suspected, discontinue HYMPAVZI and initiate appropriate medical treatment.
5.2 Hypersensitivity
5 unchanged lines

Use in specific populations

Changed1 removed
13 unchanged lines
8.4 Pediatric Use
The safety and effectiveness of HYMPAVZI to prevent or reduce the frequency of bleeding episodes in hemophilia A or B with and without inhibitors have been established in pediatric patients 6 years of age and older [see Clinical Studies (14.1, 14.2, 14.3)]. Use of HYMPAVZI in pediatric patients for this indication is supported by evidence from two open‑label, multi‑center studies (BASIS and BASIS KIDS). These two studies treated 56 adolescents (12 to less than 18 years of age). BASIS KIDS treated 68 children (6 to less than 12 years of age). Efficacy and adverse reaction profile were comparable between pediatric patients and adults [see Adverse Reactions (6.1) and, Clinical Studies (14.1, 14.2, 14.3)]. Differences observed in steady‑state pharmacokinetic (PK) exposures between pediatric patients and adults were mostly accounted for by body weight [see Clinical Pharmacology (12.3)].
The safety and effectiveness of HYMPAVZI have not been established in pediatric patients younger than 6 years of age.
2 unchanged lines

Patient counseling information

Changed124 words added, 59 removed
2 unchanged lines
•Ensure that patients and caregivers who will administer HYMPAVZI receive appropriate training and instruction on the proper storage, use and handling of HYMPAVZI from a healthcare professional.
Thromboembolic Events Inform patients and/or caregivers that HYMPAVZI increases coagulation potential. Discuss the appropriate dosing of concomitant agents such as FVIII or FIX with the patient prior to starting on HYMPAVZI prophylaxis. Advise the patient to discontinue HYMPAVZI and seek immediate medical attention if any signs or symptoms of thromboembolism occur [see Warnings and Precautions (5.1)].
Thromboembolic Events Inform patients and/or caregivers that HYMPAVZI increases coagulation potential. Discuss the appropriate dosing of concomitant agents such as FVIII or FIX with the patient prior to starting on HYMPAVZI prophylaxis. Inform patients of signs and symptoms of thromboembolic events, including swelling, warmth, pain or redness in the arms or legs; shortness of breath; pain in chest or upper back; rapid heart rate; coughing up blood; faintness or dizziness; sudden or severe headache; numbness of the face; eye pain or swelling; vision problems; confusion; difficulty with speech; weakness or numbness on one side of the body. Advise the patient to discontinue HYMPAVZI and seek immediate medical attention if any signs or symptoms of thromboembolism occur [see Warnings and Precautions (5.1)].
Hypersensitivity Inform patients and/or caregivers that hypersensitivity reactions such as rash and pruritus are possible. Advise patients to discontinue HYMPAVZI and seek immediate emergency treatment if a severe hypersensitivity reaction occurs [see Warnings and Precautions (5.2)].
1 unchanged line
This product’s labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
US License No. 2001 Distributed by Pfizer Labs Division of Pfizer Inc. New York, NY 10001 LAB-1556-45.0

Patient information

Changed47 words added, 5 removed
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 611/2026
PATIENT INFORMATION HYMPAVZI® (him-PAV-zee) (marstacimab-hncq) injection, for subcutaneous use
3 unchanged lines
How should I use HYMPAVZI? See the detailed “Instructions for Use” that comes with your HYMPAVZI for information on how to inject a dose of HYMPAVZI, and how to properly throw away (dispose of) used HYMPAVZI prefilled syringe or HYMPAVZI prefilled pen. •Use HYMPAVZI exactly as prescribed by your healthcare provider. •Your healthcare provider will provide instructions for stopping (discontinuing) your current treatment when switching from factor- or non-factor-based medicines or bypassing agents to HYMPAVZI. •HYMPAVZI comes in two different strengths in a single-dose prefilled syringe or single-dose prefilled pen. •HYMPAVZI is given as an injection under your skin (subcutaneous injection) by you or your caregiver. •People 12 years of age and older, or their caregiver may inject HYMPAVZI if your healthcare provider decides that it is appropriate. Your healthcare provider should show you or your caregiver how to inject HYMPAVZI before the first injection. •Do not inject yourself or someone else until you have been shown how to inject HYMPAVZI. •Inject HYMPAVZI 1 time a week on the same day each week. Inject HYMPAVZI at any time of day. • Dosing for adults and children 12 years of age and older: oYour first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose as prescribed by your healthcare provider. oIf you miss a maintenance dose of 150 mg of HYMPAVZI: ▪Give the dose as soon as possible before the day of your next scheduled dose, and then continue with your usual weekly dosing schedule. You may inject your next dose at your regularly scheduled time or continue dosing based on the new day you injected your missed dose. In case you are not sure when to inject HYMPAVZI, call your healthcare provider. ▪If more than 13 days have passed since your last dose was given, you will need to restart with a loading dose. Call your healthcare provider right away for dosing instructions. oIf you miss 1 or more doses of maintenance dose of 300 mg of HYMPAVZI: ▪Give a dose as soon as possible, and then continue with your usual weekly dosing schedule. You may inject your next dose at your regularly scheduled time or continue dosing based on the new day you injected your missed dose. In case you are not sure when to inject HYMPAVZI, call your healthcare provider. • Dosing for children 6 years to less than 12 years of age: oYour first dose (loading dose) of HYMPAVZI is 150 mg (one 150 mg injection or two 75 mg injections) as prescribed by your healthcare provider. Then you will inject a weekly (maintenance) dose as prescribed by your healthcare provider. oIf you miss a maintenance dose of 75 mg of HYMPAVZI: ▪Give the dose as soon as possible before the day of your next scheduled dose, and then continue with your usual weekly dosing schedule. You may inject your next dose at your regularly scheduled time or continue dosing based on the new day you injected your missed dose. In case you are not sure when to inject HYMPAVZI, call your healthcare provider. ▪If more than 13 days have passed since your last dose was given, you will need to restart with a loading dose. Call your healthcare provider right away for dosing instructions. oIf you miss 1 or more doses of maintenance dose of 150 mg of HYMPAVZI: ▪Give a dose as soon as possible, and then continue with your usual weekly dosing schedule. You may inject your next dose at your regularly scheduled time or continue dosing based on the new day you injected your missed dose. In case you are not sure when to inject HYMPAVZI, call your healthcare provider. •If you inject too much HYMPAVZI, call your healthcare provider or the Poison Help Line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
What are the possible side effects of HYMPAVZI? HYMPAVZI may cause serious side effects, including: • blood clots (thromboembolic events). HYMPAVZI may increase the risk for your blood to clot in blood vessels in your arm, leg, lung, or head and can be life-threatening. Blood clots have happened in people using HYMPAVZI. It is important to talk with your healthcare provider about the risk factors that may increase your risk of having a blood clot. You may have an increased risk of blood clots if you have certain risk factors. Stop using HYMPAVZI and get medical help right away if you develop any of these signs or symptoms of blood clots:
| oswelling, warmth, or pain in arms or legs oredness or discoloration in your arms or legs oshortness of breath opain in chest or upper back ofast heart rate ocoughocoughing up blood | ofeelofeeling faint or dizziness | oheadache (sudden or severe) onumbness in your face oeye pain or swelling osudden vision problems oconfusion otrouble seeingspeaking oweakness or numbness on one side of your body
• allergic reactions. HYMPAVZI may cause allergic reactions, including rash and itching. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction:
6 unchanged lines
What are the ingredients in HYMPAVZI? Active ingredient: marstacimab‑hncq Inactive ingredients: edetate disodium, histidine, L-histidine monohydrochloride, polysorbate 80, sucrose, and water for injection
This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com. US License No. 2001 Distributed by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001 LAB-1575-34.0 For more information, go to website www.HYMPAVZI.com or call 1-800-438-1985.

PRINCIPAL DISPLAY PANEL – 150 mg/mL Prefilled Pen

Changed1 word added, 1 removed
2 unchanged lines
Pfizer
HYMPAVZITMHYMPAVZI® (marstacimab-hncq) Injection
150 mg/mL
2 unchanged lines

PRINCIPAL DISPLAY PANEL – 150 mg/mL Prefilled Pen Carton

Changed1 removed
3 unchanged lines
Pfizer
HYMPAVZI TM® (marstacimab-hncq) Injection
150 mg/mL
4 unchanged lines

PRINCIPAL DISPLAY PANEL - 150 mg/mL Prefilled Syringe

Changed1 word added, 1 removed
2 unchanged lines
Single-Dose
HYMPAVZITMHYMPAVZI® (marstacimab-hncq) Injection
150 mg/mL
4 unchanged lines

PRINCIPAL DISPLAY PANEL - 150 mg/mL Prefilled Syringe Carton

Changed1 removed
3 unchanged lines
Pfizer
HYMPAVZI TM® (marstacimab-hncq) Injection
150 mg/mL
4 unchanged lines

Unchanged: Indications and usage, Dosage forms and strengths, Contraindications, Adverse reactions, Drug interactions, Overdosage, Description, Clinical pharmacology, Nonclinical toxicology, Clinical studies, How supplied, Instructions for use, PRINCIPAL DISPLAY PANEL – 75 mg/0.5 mL Prefilled Pen, PRINCIPAL DISPLAY PANEL – 75 mg/0.5 mL Prefilled Pen Carton, PRINCIPAL DISPLAY PANEL – 75 mg/0.5 mL Prefilled Syringe, PRINCIPAL DISPLAY PANEL – 75 mg/0.5 mL Prefilled Syringe Carton.

Every version

8 versions of set a2cc631e-13a6-40c2-acf9-065ccedfb90a, newest first.
VersionPublished on DailyMedCompareSPL file
8Nov 16, 2026Shown belowDownload .zip
7Jun 23, 2026With version 6Download .zip
6Jun 17, 2026With version 5Download .zip
5Dec 22, 2025With version 4Download .zip
4Nov 17, 2025With version 3Download .zip
3Sep 29, 2025With version 2Download .zip
2Feb 12, 2025With version 1Download .zip
1Nov 7, 2024First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.